Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Transplantation for Myeloma and Plasma Cell Leukemia – A Single-Institution Experience

Ramasamy, Karthik; Mahmood, Shameem; Lim, ZiYi; Corderoy, Sophie; Devereux, Stephen; Mufti, Ghulam J.; Pagliuca, Antonio; Schey, Stephen

doi:10.1016/j.clml.2011.03.004

Cited by 4 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To overcome this limitation, Maloney et al reported that combining a cytoreductive autograft with a nonmyeloablative allograft lowered transplant-related mortality by approximately 15% 12. Meanwhile, Ramasamy et al reported that alemtuzumab-based reduced intensity conditioning allogeneic transplantation 13. Although progression-free survival of their patient cohort was comparable to previously published data of reduced intensity conditioning allogeneic transplantation in myeloma, there is no plateau on the survival curves, with a significant transplant-related mortality of 21%.…”

Section: Discussionmentioning

confidence: 79%

Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation

Ozasa

Hotta²,

Yoshimura³

et al. 2012

IMCRJ

View full text Add to dashboard Cite

Plasma cell leukemia (PCL) is a rare disease that represents approximately 4% of plasma cell malignant disorders. PCL consists of two variants: primary PCL presents in patients with no previous history of multiple myeloma, while secondary PCL consists of a leukemic transformation in a previously recognized multiple myeloma. Primary PCL is an extremely resistant, rapidly progressive, fatal disease, with a median overall survival of 6.8 months. There is no standard therapeutic strategy, because no treatment option has been prospectively evaluated. We describe a successful case of newly diagnosed primary PCL, treated with a regimen that included bortezomib, followed by auto stem cell transplantation and nonmyeloablative allogeneic stem cell transplantation. Our patient has maintained remission status for over 12 months since undergoing the allogeneic stem cell transplantation. This strategy is promising for PCL, which, though an extremely resistant disease, may become curable.

show abstract

Section: Discussionmentioning

confidence: 79%

Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation

Ozasa

Hotta²,

Yoshimura³

et al. 2012

IMCRJ

View full text Add to dashboard Cite

show abstract

Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: A Focus on Hematopoietic Cell Transplantation

Nishihori

Kar

Baz

et al. 2013

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Primary plasma cell leukemia (pPCL) is an uncommon but aggressive plasma cell malignancy associated with frequent extramedullary involvement, high-risk cytogenetic abnormalities, and frequent organ dysfunction, ultimately resulting in poor prognosis. Here we review recent advances in our understanding of the molecular and biological aspects of PCL and summarize therapeutic progress occurring over the past 2 decades. pPCL is distinguished from secondary PCL arising from multiple myeloma. The molecular and immunophenotypic changes of pPCL are often distinct from those seen in secondary PCL and multiple myeloma. The availability of novel agents (ie, proteasome inhibitors and immunomodulatory agents) and the increasing use of hematopoietic cell transplantation strategies have resulted in better outcomes, although long-term survival remains poor. Development of complex treatment algorithms that combine novel agents as induction therapy, as part of conditioning regimens for hematopoietic cell transplantation (autologous or allogeneic), or as post-transplantation remission strategies are logical and may translate into improved survival in patients with PCL.

show abstract

Monoclonal antibody therapy in multiple myeloma

Touzeau¹,

Moreau²,

Dumontet

2017

Leukemia

View full text Add to dashboard Cite

The therapeutic landscape of multiple myeloma (MM) has evolved spectacularly over the past decade with the discovery and validation of proteasome inhibitors and immunomodulatory agents as highly active agents, both in front-line therapy as well as in the relapse and maintenance settings. Although previous attempts to apply available monoclonal antibodies (Mabs) to the treatment of patients with MM has until recently been disappointing, novel targets specifically explored in the context of MM have recently lead to the first approvals of Mabs for the treatment of patients with MM. We have performed a literature search to identify preclinical targeting of MM, including in vitro and in vivo models using monoclonal antibodies, as well as clinical trials of monoclonal antibodies in patients with MM. Sources used were peer-reviewed publications, congress abstracts and on-line clinical trials data (such as clinicaltrials.gov). Several targets have been evaluated in preclinical models and a growing number of agents are being evaluated in clinical trials, as single agents or in combination and under various antibody formats. Two agents, targeting for the first time CD38 and SLAMF7, respectively, have recently been approved for the treatment of patients with MM. The recent approval of these two antibodies is expected to have a strong impact on treatment modalities and outcome in patients with MM, including both transplant eligible and elderly patients.

show abstract

Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Transplantation for Myeloma and Plasma Cell Leukemia – A Single-Institution Experience

Cited by 4 publications

References 16 publications

Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation

Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation

Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: A Focus on Hematopoietic Cell Transplantation

Monoclonal antibody therapy in multiple myeloma

Contact Info

Product

Resources

About